Biography

Michel Vounatsos joined our Board in 2023 and serves as Chair of our Commercial Committee and as a member of our Research and Development Committee.

Mr. Vounatsos brings to our Board extensive global leadership and management experience in the biopharmaceutical industry, including more than 25 years of service at leading companies. His expertise includes significant commercial experience in China and worldwide in the areas of primary care and neuroscience.

In addition to serving on our Board, he has also served on other public company boards, including Revvity, Inc. (NYSE) since 2020. He also serves on the advisory board of Tsinghua University School of Pharmaceutical Sciences in Beijing, China and as Chairman of the Supervisory Board of Liryc, the Electrophysiology and Heart Modeling Institute at the University of Bordeaux.

Previously, Mr. Vounatsos served as Chief Executive Officer and member of the Board of Directors of Biogen, Inc. (Nasdaq) from 2017 to 2022, after serving as Executive Vice President and Chief Commercial Officer in 2016. Prior to joining Biogen, Mr. Vounatsos held various roles of increasing responsibility at Merck & Co. from 1996 to 2016, including President of Primary Care and Merck Customer Centricity, President of MSD China, and other leadership positions across Europe. In these positions, he was responsible for strategic and business development decisions, led several strategic alliances, and helped the business grow and significantly increase performance.

Mr. Vounatsos received an MBA from HEC School of Management in Paris, France and a C.S.C.T. (Certificate of Clinical and Therapeutic Synthesis) in Medicine from Université Victor Segalen, Bourdeaux II, France.